Upadacitinib Effective Long Term for AD in Adolescents

An analysis of three phase 3 trials reported relief with upadacitinib through 76 weeks in adolescents with AD.
Medscape Medical News

source https://www.medscape.com/viewarticle/upadacitinib-effective-long-term-ad-adolescents-2024a1000jmf?src=rss